GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenetp Inc (STU:NJT) » Definitions » Capex-to-Revenue

Regenetp (STU:NJT) Capex-to-Revenue : 0.00 (As of Mar. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Regenetp Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Regenetp's Capital Expenditure for the three months ended in Mar. 2023 was €0.00 Mil. Its Revenue for the three months ended in Mar. 2023 was €0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.


Regenetp Capex-to-Revenue Historical Data

The historical data trend for Regenetp's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenetp Capex-to-Revenue Chart

Regenetp Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Dec19 Dec20 Dec21 Dec22
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.90 0.49 0.13 0.01 0.05

Regenetp Quarterly Data
Apr18 Jul18 Oct18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 - - - -

Competitive Comparison of Regenetp's Capex-to-Revenue

For the Biotechnology subindustry, Regenetp's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenetp's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenetp's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Regenetp's Capex-to-Revenue falls into.



Regenetp Capex-to-Revenue Calculation

Regenetp's Capex-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.035) / 0.768
=0.05

Regenetp's Capex-to-Revenue for the quarter that ended in Mar. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regenetp  (STU:NJT) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Regenetp Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Regenetp's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenetp (STU:NJT) Business Description

Traded in Other Exchanges
Address
1960 South 4250 West, Salt Lake City, UT, USA, 84104
Regenetp Inc Formerly PolarityTE Inc is a clinical-stage biotechnology company developing regenerative tissue products and biomaterials. It's focused on transforming the lives of patients by discovering, designing, and developing regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. Its product includes SkinTE used for repair, reconstruction, replacement, or regeneration of the skin in patients who have or require treatment of acute and chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. It operates in two segments: the regenerative medicine business segment and the contract research segment.

Regenetp (STU:NJT) Headlines

No Headlines